A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers

Thumbnail Image

Files

bcbcr.s29425.pdf (1.22 MB)

Links to Files

https://journals.sagepub.com/doi/full/10.4137/BCBCR.S29425

Permanent Link

https://doi.org/10.4137%2FBCBCR.S29425
 http://hdl.handle.net/11603/24418

Collections

UMBC Biological Sciences Department

Author/Creator

Author/Creator ORCID

https://orcid.org/0000-0001-7603-9276

Date

2015-11-02

Type of Work

journal articles
Text

Department

Program

Citation of Original Publication

Nahas et al. A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer: Basic and Clinical Research 2015:9(S2) 35–43 doi:10.4137/BCBCR.S29425.

Rights

This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Attribution-NonCommercial 3.0 United States

Subjects

Abstract

Immunotherapy for cancer has been a focus 50 years ago. At the time, this treatment was developed prior to cloning of the cytokines, no knowledge of regulatory T-cells, and very little information that mesenchymal stem cells (MSCs) (originally colony forming unit-fibroblasts [CFU-F]) could be licensed by the inflammatory microenvironment to suppress an immune response. Given the information available at that time, mononuclear cells from the peripheral blood were activated ex vivo and then replaced in the patients with tumor. The intent was to harness these activated immune cells to target the cancer cells. These studies did not lead to long-term responses because the activated cells when reinfused into the patients were an advantage to the resident MSCs, which can home the tumor and then become suppressive in the presence of the immune cells. The immune suppression caused by MSCs would also expand regulatory T-cells, resulting instead in tumor protection. As time progressed, these different fields converged into a new approach to use immunotherapy for cancer. This article discusses these approaches and also reviews chimeric antigen receptor in the context of future treatments for solid tumors, including breast cancer.